MannKind stock is nearing a breakout as the FDA reviews its Afrezza paediatric application, the first new insulin for US children in a century. CEO Michael Castagna confirmed the FDA acceptance, sparking optimism over MannKind expanding diabetes pipeline. The firm also plans to relaunch its BlueHale smart inhaler to target the $5.6 billion paediatric diabetes market.